NCT02152982 2026-04-13
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
National Cancer Institute (NCI)
Blaze Bioscience Inc.
National Cancer Institute (NCI)
Y-mAbs Therapeutics
University of Utah
M.D. Anderson Cancer Center